These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15785380)

  • 1. In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: implications for the control of Graft-versus-host disease.
    Collin MP; Munster D; Clark G; Wang XN; Dickinson AM; Hart DN
    Transplantation; 2005 Mar; 79(6):722-5. PubMed ID: 15785380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
    Ratzinger G; Reagan JL; Heller G; Busam KJ; Young JW
    Blood; 2003 Feb; 101(4):1422-9. PubMed ID: 12393688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
    Simpson D
    BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fast appearance of donor dendritic cells in human skin: dynamics of skin and blood dendritic cells after allogeneic hematopoietic cell transplantation.
    Auffermann-Gretzinger S; Eger L; Bornhäuser M; Schäkel K; Oelschlaegel U; Schaich M; Illmer T; Thiede C; Ehninger G
    Transplantation; 2006 Mar; 81(6):866-73. PubMed ID: 16570010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMRF-44 antibody-mediated depletion of activated human dendridic cells: a potential means for improving allograft survival.
    Koppi T; Munster DJ; Brown L; MacDonald KP; Hart DN
    Transplantation; 2003 May; 75(10):1723-30. PubMed ID: 12777863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab depletes dendritic cells more effectively in blood than in skin: a pilot study in patients with chronic lymphocytic leukemia.
    Auffermann-Gretzinger S; Eger L; Schetelig J; Bornhäuser M; Heidenreich F; Ehninger G
    Transplantation; 2007 May; 83(9):1268-72. PubMed ID: 17496545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated circulating dendritic cells after hematopoietic stem cell transplantation predict acute graft-versus-host disease.
    Lau J; Sartor M; Bradstock KF; Vuckovic S; Munster DJ; Hart DN
    Transplantation; 2007 Apr; 83(7):839-46. PubMed ID: 17460553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAMPATH-1 antibodies in stem-cell transplantation.
    Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
    Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
    Jordan MB; McClain KL; Yan X; Hicks J; Jaffe R
    Pediatr Blood Cancer; 2005 Mar; 44(3):251-4. PubMed ID: 15390358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation.
    Giralt S
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S36-43. PubMed ID: 16720202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rediscovering alemtuzumab: current and emerging therapeutic roles.
    Gribben JG; Hallek M
    Br J Haematol; 2009 Mar; 144(6):818-31. PubMed ID: 19183194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.
    Seldon TA; Pryor R; Palkova A; Jones ML; Verma ND; Findova M; Braet K; Sheng Y; Fan Y; Zhou EY; Marks JD; Munro T; Mahler SM; Barnard RT; Fromm PD; Silveira PA; Elgundi Z; Ju X; Clark GJ; Bradstock KF; Munster DJ; Hart DN
    Leukemia; 2016 Mar; 30(3):692-700. PubMed ID: 26286117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
    Hale G; Waldmann H
    Bone Marrow Transplant; 1994 May; 13(5):597-611. PubMed ID: 8054913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients.
    Kirsch BM; Haidinger M; Zeyda M; Böhmig GA; Tombinsky J; Mühlbacher F; Watschinger B; Hörl WH; Säemann MD
    Transpl Immunol; 2006 Nov; 16(3-4):254-7. PubMed ID: 17138063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells.
    Hock BD; Starling GC; Daniel PB; Hart DN
    Immunology; 1994 Dec; 83(4):573-81. PubMed ID: 7875738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
    Dodero A; Carrabba M; Milani R; Rizzo E; Raganato A; Montefusco V; Farina L; Milanesi M; Longoni P; Carlo-Stella C; Corradini P
    Exp Hematol; 2005 Aug; 33(8):920-7. PubMed ID: 16038785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
    Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
    Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells.
    Ayuk FA; Fang L; Fehse B; Zander AR; Kröger N
    Exp Hematol; 2005 Dec; 33(12):1531-6. PubMed ID: 16338496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of alemtuzumab on neoplastic B cells.
    Golay J; Manganini M; Rambaldi A; Introna M
    Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definition of the variables affecting efficacy of immunodepletion ex vivo of peripheral blood progenitor cell grafts by alemtuzumab (Campath in the bag).
    Novitzky N; Davison G; Abdulla R; Mowla S
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1753-9. PubMed ID: 24120379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.